BMC Pharmacology and Toxicology· 2026Q2
Ultrasound-responsive doxorubicin microbubbles engineered by QbD: enhanced in vitro anti-breast-cancer efficacy with attenuated cardiac cell toxicity
- 1citations
- Q2SCImago
- 2026year
Short summary
Ultrasound-responsive doxorubicin microbubbles engineered using Quality by Design (QbD) show enhanced in vitro anti-breast-cancer efficacy (IC₅₀ = 0.0013 µg/mL vs. 0.62 µg/mL for free doxorubicin) and significantly reduced cardiac cell toxicity (IC₅₀ ≈ 8.72 µg/mL without ultrasound).
AI-generated from the title and abstract; the full text is not read.
Key points
- A Quality by Design (QbD) strategy was used to engineer doxorubicin-loaded microbubbles with controlled size (≈ 3.2 µm) and encapsulation efficiency (≈ 70–75%).
- Ultrasound activation triggered rapid drug release (> 80% within 40 s) with minimal leakage under non-activated conditions.
- Optimized microbubbles showed significantly enhanced in vitro efficacy against MCF-7 breast cancer cells (IC₅₀ = 0.0013 µg/mL) compared to free doxorubicin (IC₅₀ = 0.62 µg/mL).
- Cardiac toxicity in H9c2 cells was attenuated (IC₅₀ ≈ 8.72 µg/mL), resulting in a >10³-fold improvement in therapeutic selectivity upon ultrasound activation.
AI-generated from the title and abstract; the full text is not read.
Abstract
Abstract Ultrasound-responsive microbubbles provide a powerful means for externally regulated drug delivery, yet their translation is often constrained by empirical formulation approaches and limited therapeutic selectivity. In this study, a Quality by Design (QbD) strategy was implemented to rationally engineer doxorubicin-loaded chitosan microbubbles with predictable physicochemical and biological performance. A Box–Behnken experimental design enabled systematic optimization of critical formulation variables, yielding a statistically validated design space governing microbubble size (≈ 3.2 µm), encapsulation efficiency (≈ 70–75%), and ultrasound-triggered burst release (> 80% within 40 s). The optimized formulation demonstrated minimal baseline drug leakage under non-activated conditions, while brief ultrasound exposure induced rapid, on-demand release. In vitro evaluation revealed a marked enhancement of anticancer efficacy in MCF-7 breast cancer cells following ultrasound activation, with a dramatic reduction in IC₅₀ to 0.0013 µg/mL compared with free doxorubicin (0.62 µg/mL). In contrast, cardiotoxicity in H9c2 cardiomyoblast cells remained attenuated under non-triggered conditions (IC₅₀ ≈ 8.72 µg/mL), resulting in a > 10³-fold improvement in therapeutic selectivity upon ultrasound activation. Mechanistic analysis indicated that intact microbubbles restrict passive drug diffusion, whereas ultrasound-induced cavitation and transient membrane permeabilization enable efficient intracellular delivery at the target site. Overall, this work demonstrates that integrating QbD-driven formulation control with spatially confined ultrasound activation can substantially expand the therapeutic window of doxorubicin, offering a transferable framework for precision, stimulus-responsive drug delivery without chemical modification of the parent drug.
The authors' abstract, as published at the source. BMC Pharmacology and Toxicology, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Biomedical Engineering
Biomedical EngineeringEngineering